ArticleBMC gastroenterology2026
The LGR5/TFF2 ratio as a stem cell biomarker predicts high-risk status in chronic atrophic gastritis: a retrospective cohort study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The mechanical niche in gastric precancer: extracellular matrix remodeling, mechanotransduction, and stem-cell fate.Frontiers in cell and developmental biology · 2026Review
- Research Status and Prospects ofGastroenterology research and practice · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundChronic atrophic gastritis (CAG) severity risk assessment remains challenging due to limitations of current static histologic/endoscopic tools. We evaluated the leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5)/trefoil factor 2 (TFF2) ratio - quantifying gastric stem cell niche imbalance- as a dynamic biomarker for high-risk CAG (OLGA/OLGIM III-IV).
methodsIn a retrospective cohort (n = 60 CAG patients), we constructed four prediction models (Baseline: demographics; Clinical: +H. pylori/family history; Endoscopic; Full: +LGR5/TFF2 ratio) using Firth penalized regression. Model performance was assessed via area under the curve (AUC), Akaike (AIC), and Bayesian (BIC) information criteria, and likelihood ratio tests. Restricted cubic splines and subgroup analyses validated threshold effects.
resultsThe LGR5/TFF2 ratio > 1.066 (AUC = 0.93) identified high-risk CAG with 48.5-fold increased odds (95% CI: 4.07-578.51, P = 0.002), outperforming endoscopic/histologic models (ΔAUC = + 0.15). A nonlinear dose-response relationship revealed sharp risk escalation beyond this threshold. The high-ratio group (n = 20) exhibited 60.00% prevalence of prior H. pylori eradication, Wnt activation (β-catenin↑32.3%, CyclinD1↑90%, P < 0.001), and stronger endoscopic correlation (ρ = 0.42 for IM nodules) than traditional factors (ρ = 0.28 for H. pylori).
conclusionThe LGR5/TFF2 ratio is the first biomarker to molecularly define CAG severity risk by quantifying stem cell niche imbalance (LGR5↑/TFF2↓), achieving superior accuracy (AUC = 0.93) and identifying high-risk cases missed by current methods. Its integration into clinical practice could transform risk-stratified surveillance paradigms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.